Table 3.
HCC suppression in xenograft models by inhibiting the JAK/STAT signaling pathway.
| Agent | Target Molecule (Inhibited Molecule) |
HCC Cell Line Transplanted | Phenotype | Reference |
|---|---|---|---|---|
| miR-515-5p | IL-6 (STAT3) |
HepG2 | Inhibited migration and invasion of HCC cells | [160] |
| Etomidate | JAK2 | HepG2 | Inhibition of tumor growth Increase in animal survival |
[152] |
| C1QTNF1-AS1 | miR-221-3p (STAT3) |
HepG2, Huh-7 |
Reduced tumor volumes | [161] |
| Cantharidin | EphB4 receptor (JAK2, STAT3) |
SMMC-7721 | Reduced tumor growth | [162] |
| Nitidine chloride | JAK1, STAT3 | HepG2 | Reduced tumor volumes | [163] |
| Dehydrocrenatidine | JAK2 | HepG2 | Reduced invasion of HCC Inhibition of CSC phenotypes |
[164] |
| CIMO | JAK1, JAK2, STAT3 | Huh-7 | Reduced tumor growth | [165] |
| Napabucasin | STAT3 | Hepa1-6 | Reduced tumor volumes Tumor regression in 25% mice |
[158] |
| OPB-31121 | STAT3 | Huh-7, HepG2 |
Reduced tumor growth | [166] |